WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib‐treated CML patient

How to treat CML patients who are resistant to inhibitors of BCR‐ABL tyrosine kinase such as Imatinib is a very important and urgent issue in clinical hematology. Here, we report a case of Imatinib‐treated CML in which intradermally administered WT1 peptide vaccine elicited WT1‐specific immune respo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of haematology 2010-10, Vol.85 (4), p.358-360
Hauptverfasser:	Oji, Yusuke, Oka, Yoshihiro, Nishida, Sumiyuki, Tsuboi, Akihiro, Kawakami, Manabu, Shirakata, Toshiaki, Takahashi, Kazuko, Murao, Ayako, Nakajima, Hiroko, Narita, Miwako, Takahashi, Masuhiro, Morita, Satoshi, Sakamoto, Junichi, Tanaka, Toshio, Kawase, Ichiro, Hosen, Naoki, Sugiyama, Haruo
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents - therapeutic use Benzamides Cancer Vaccines - chemistry Cancer Vaccines - immunology Cancer Vaccines - therapeutic use CML Combined Modality Therapy Drug Resistance, Neoplasm Female Fusion Proteins, bcr-abl - antagonists & inhibitors Humans Imatinib Imatinib Mesylate immunotherapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy Neoplasm, Residual Piperazines - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Pyrimidines - therapeutic use RNA, Messenger T-Lymphocytes, Cytotoxic - immunology Vaccines, Subunit - immunology Vaccines, Subunit - therapeutic use WT1 peptide vaccine WT1 Proteins - chemistry WT1 Proteins - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!